SI2022497T1 - Peroralna sestava, vsebujoäśa 3-(5-(4-(ciklopentiloksi)-2- hidrobenzoil)-2)(3-hidroksi-1,2-benzizoksazol-6-il)metoksi fenil propionsko kislino ali sol le-te - Google Patents

Peroralna sestava, vsebujoäśa 3-(5-(4-(ciklopentiloksi)-2- hidrobenzoil)-2)(3-hidroksi-1,2-benzizoksazol-6-il)metoksi fenil propionsko kislino ali sol le-te

Info

Publication number
SI2022497T1
SI2022497T1 SI200731487T SI200731487T SI2022497T1 SI 2022497 T1 SI2022497 T1 SI 2022497T1 SI 200731487 T SI200731487 T SI 200731487T SI 200731487 T SI200731487 T SI 200731487T SI 2022497 T1 SI2022497 T1 SI 2022497T1
Authority
SI
Slovenia
Prior art keywords
hydroxybenzoylć
benzisoxazol
cyclopentyloxy
hydroxy
salt
Prior art date
Application number
SI200731487T
Other languages
English (en)
Inventor
Sahoe Kakuda
Tatsuhito Yahata
Masashi Kaneko
Original Assignee
Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd. filed Critical Toyama Chemical Co., Ltd.
Publication of SI2022497T1 publication Critical patent/SI2022497T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI200731487T 2006-05-26 2007-05-25 Peroralna sestava, vsebujoäśa 3-(5-(4-(ciklopentiloksi)-2- hidrobenzoil)-2)(3-hidroksi-1,2-benzizoksazol-6-il)metoksi fenil propionsko kislino ali sol le-te SI2022497T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006146315 2006-05-26
JP2006146257 2006-05-26
EP07744105.3A EP2022497B1 (en) 2006-05-26 2007-05-25 Oral composition comprising 3-[5-[4-(cyclopentyloxy) -2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxy¨phenyl¨propionic acid or salt thereof
PCT/JP2007/060671 WO2007138997A1 (ja) 2006-05-26 2007-05-25 ３－｛５－［４－（シクロペンチルオキシ）－２－ヒドロキシベンゾイル］－２－［（３－ヒドロキシ－１，２－ベンズイソオキサゾール－６－イル）メトキシ］フェニル｝プロピオン酸またはその塩を含有する経口用組成物

Publications (1)

Publication Number Publication Date
SI2022497T1 true SI2022497T1 (sl) 2014-08-29

Family

ID=38778517

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731487T SI2022497T1 (sl) 2006-05-26 2007-05-25 Peroralna sestava, vsebujoäśa 3-(5-(4-(ciklopentiloksi)-2- hidrobenzoil)-2)(3-hidroksi-1,2-benzizoksazol-6-il)metoksi fenil propionsko kislino ali sol le-te

Country Status (21)

Country Link
US (1) US8093289B2 (sl)
EP (1) EP2022497B1 (sl)
JP (1) JP5161077B2 (sl)
KR (1) KR101394121B1 (sl)
CN (1) CN101454003B (sl)
AU (1) AU2007268772B2 (sl)
BR (1) BRPI0709710A2 (sl)
CA (1) CA2653023C (sl)
CY (1) CY1115312T1 (sl)
DK (1) DK2022497T3 (sl)
ES (1) ES2463455T3 (sl)
IL (1) IL195417A (sl)
MX (1) MX2008015015A (sl)
NO (1) NO20084634L (sl)
NZ (1) NZ573035A (sl)
PL (1) PL2022497T3 (sl)
PT (1) PT2022497E (sl)
RU (1) RU2436576C2 (sl)
SI (1) SI2022497T1 (sl)
WO (1) WO2007138997A1 (sl)
ZA (1) ZA200810018B (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2262477A1 (en) * 2008-03-04 2010-12-22 F. Hoffmann-La Roche AG Process for preparing concentrated aqueous micellar solutions
MX2010010440A (es) * 2008-03-27 2010-12-15 Toyama Chemical Co Ltd Uso de derivado de benzofenona o su sal e inhibidor de tnfa en combinacion y composicion farmaceutica que contiene el derivado o su sal y el inhibidor.
US9066977B2 (en) * 2008-04-22 2015-06-30 Toyama Chemical Co., Ltd. Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components
EP2140861A1 (en) 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
JP2015533134A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 錠剤の機械的安定性に適切な少なくとも１種の水和物形成活性物質及び／又はアジュバントを含有する機械的に安定な錠剤、特にアルギニン含有錠剤の製造における選択的に水分調整された打錠材料の使用
CN110575762B (zh) * 2018-06-07 2024-03-26 温州大学新材料与产业技术研究院 一种有机烷基钆水性分散体系的制备方法
WO2021257887A1 (en) * 2020-06-19 2021-12-23 The Board Of Trustees Of The Leland Stanford Junior University Use of inhibitors of the activator protein 1 (ap-1) for preventing adhesions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3670080A (en) * 1969-03-06 1972-06-13 Shionogi & Co Process for stabilization of a composition of 2{60 ,3{60 -epithio-androstanes and composition obtained thereby
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
JPS56110612A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
JPS5942313A (ja) * 1982-09-01 1984-03-08 Teijin Ltd ポリビニルポリピロリドンを用いた製剤
JPS60190723A (ja) * 1984-03-09 1985-09-28 Yamanouchi Pharmaceut Co Ltd 難溶性薬物の溶解速度向上方法
DK1445249T3 (da) * 2001-11-16 2012-12-17 Toyama Chemical Co Ltd Nye bensophenon-derivater eller salte deraf

Also Published As

Publication number Publication date
CN101454003A (zh) 2009-06-10
IL195417A (en) 2014-03-31
RU2436576C2 (ru) 2011-12-20
KR101394121B1 (ko) 2014-05-14
US20090163562A1 (en) 2009-06-25
CA2653023C (en) 2015-07-07
IL195417A0 (en) 2009-08-03
PT2022497E (pt) 2014-07-17
MX2008015015A (es) 2008-12-05
NZ573035A (en) 2010-08-27
DK2022497T3 (da) 2014-05-19
BRPI0709710A2 (pt) 2011-07-26
EP2022497B1 (en) 2014-04-30
EP2022497A1 (en) 2009-02-11
AU2007268772B2 (en) 2012-03-15
PL2022497T3 (pl) 2014-09-30
RU2008151757A (ru) 2010-07-10
CY1115312T1 (el) 2017-01-04
NO20084634L (no) 2008-12-19
CN101454003B (zh) 2011-06-01
ZA200810018B (en) 2010-02-24
EP2022497A4 (en) 2013-02-13
AU2007268772A1 (en) 2007-12-06
ES2463455T3 (es) 2014-05-28
KR20090021167A (ko) 2009-02-27
JPWO2007138997A1 (ja) 2009-10-08
US8093289B2 (en) 2012-01-10
CA2653023A1 (en) 2007-12-06
JP5161077B2 (ja) 2013-03-13
WO2007138997A1 (ja) 2007-12-06

Similar Documents

Publication Publication Date Title
SI2097381T1 (sl) 4-(4-((4-kloro-3-(trifluorometil)fenil))karbamoil)amino)-3- fluorofenoksi)-n-metilpiridin-2-karbokasamid monohidrat
PL2037866T3 (pl) Środki smakowe dla kompozycji do higieny jamy ustnej
HK1129566A1 (en) Oral preparation comprising pioglitazone
EP2036559A4 (en) NEW PAVER PREPARATION
SI2022497T1 (sl) Peroralna sestava, vsebujoäśa 3-(5-(4-(ciklopentiloksi)-2- hidrobenzoil)-2)(3-hidroksi-1,2-benzizoksazol-6-il)metoksi fenil propionsko kislino ali sol le-te
HK1142001A1 (en) Preparation for transnasal application
HK1092777A1 (en) Phenoxyacetic acid derivatives
PL1935395T3 (pl) Doustna kompozycja
EP2011482A4 (en) SOLID PREPARATION FOR ORAL APPLICATION
IL180674A0 (en) Improved surgical cassette
EP1954298A4 (en) DISPENSING SYSTEM FOR ORAL THERAPEUTIC CONNECTION
EP2073685A4 (en) ENDOSCOPIC POSITIONING SYSTEM
EP2068934B8 (en) Formulations comprising cyclic compounds
PT1906067E (pt) Cassete cirúrgica
EP2017275A4 (en) BENZISOXAZOLE COMPOUND
EP2187897A4 (en) COMPOSITION TO PREVENT VIRUS INFECTIONS WITH POLY GAMMA GLUTAMINE ACID
DK1985303T3 (da) Oral sammensætning indeholdende interferon-alpha
EP1858841A4 (en) STERILIZING COMPOSITION CONTAINING W-ALKOXYPEROXY CARBOXYLIC ACID
IL198760A0 (en) Oral formulations
EP2047856A4 (en) AGENT FOR PREVENTING INFECTION
PL1771151T3 (pl) Kompozycja, zawierająca kwas fluorowodorowy, do hamowania erozji zębów
PT1849360E (pt) Novo uso para ácido 2-hidroxi-4-metiltiobutanóico (hmtb)
PL373776A1 (en) Oral pharmaceutical compound
WO2009069643A1 (ja) ３－｛５－［４－（シクロペンチルオキシ）－２－ヒドロキシベンゾイル］－２－［（３－ヒドロキシ－１，２－ベンズイソオキサゾール－６－イル）メトキシ］フェニル｝プロピオン酸またはその塩を含有する固体分散体またはその組成物
AU2006901973A0 (en) Oral therapeutic compound delivery system